StockData
Alnylam Pharmaceuticals, Inc. logo

Alnylam Pharmaceuticals, Inc. (ALNY) bonds

ALNYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 10/3047% below fair value
$149.40−7.10 (-4.54%)

Close on Nov 18, 2026Market cap $20.01BP/E 7.8Yield –

Debt

Borrowings on the balance sheet, Sep 30, 2026

Alnylam Pharmaceuticals reports no long-term debt line

Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.

Notes and loans outstanding

As tagged in Alnylam Pharmaceuticals's 10-Q for the period ended Sep 30, 2026

IssueCouponMaturesAmount issuedCarrying value
Convertible Senior Notes Due 2027
Convertible at $286 a share
–2027$1.04B$362.80M
Convertible Senior Notes Due 2027, Additional Amount
Convertible
–2027$135.00M–
2028 Notes
Convertible at $670 a share
0.00%2028$661.30M$651.10M
Additional 2028 Notes
Convertible
–2028$86.30M–
Initial 2028 Notes
Convertible
–2028$575.00M–

Companies tag their debt differently: some list every note, others group notes by issuance year or by type, so the list may not add up to total debt. Notes that matured before today are hidden. Source: 10-Q.

Credit facilities

Revolving credit lines and other committed borrowing capacity

FacilitySize
Revolving Credit Agreement$150.00M

See a number that looks wrong?